Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. [electronic resource]
Producer: 20171225Description: 305-312 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Anthracyclines -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Bone Neoplasms -- drug therapy
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Proportional Hazards Models
- Receptor, ErbB-2 -- metabolism
- Trastuzumab -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.